BACKGROUND:Coronary artery stents can be used in clinical treatment of various lesions due to coronary artery stenosis, and different types of drug-eluting stents and bare metal stents can be used surgicaly. However, there are some differences in the therapeutic efficacy and safety among the stents made in different manufacturers. OBJECTIVE:To explore the safety of biodegradable sirolimus eluting stents from different manufacturers in the treatment of coronary artery stenosis. METHODS:Totaly 193 patients with coronary artery stenosis were enroled, including 116 males and 80 females, aged 37-81 years old. These patients were equaly divided into two groups and respectively treated with Firebird stent (MicroPort) and Partner stent (LOOP INC). Patients were folowed up for 12 months, and the restenosis rate,incidence of acute myocardial infarction, rate of coronary artery bypass graft or secondary percutaneous coronary artery interventional therapy, and mortality rate were compared between two groups. RESULTS AND CONCLUSION:After 12 months of folowed-up, there was no difference in the restenosis rate, incidence of acute myocardial infarction, rate of coronary artery bypass graft or secondary percutaneous coronary artery interventional therapy, and mortality rate between two groups (P> 0.05). During the folow-up, no adverse reaction occurred in both two groups. These findings indicate that different brands of biodegradable sirolimus eluting stents can obtain good outcomes in the treatment of coronary artery stenosis, have no adverse reaction, and exhibit a certain degree of security.